These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2835059)

  • 1. DNA topoisomerases in cancer therapy.
    Lock RB; Ross WE
    Anticancer Drug Des; 1987 Oct; 2(2):151-64. PubMed ID: 2835059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
    Lin JH; Castora FJ
    Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
    Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.
    Glisson B; Gupta R; Hodges P; Ross W
    Cancer Res; 1986 Apr; 46(4 Pt 2):1939-42. PubMed ID: 3004712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM; Latham MD; Ross WE
    Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.
    Poot M; Hiller KH; Heimpel S; Hoehn H
    Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of DNA topoisomerase inhibitors.
    Binaschi M; Zunino F; Capranico G
    Stem Cells; 1995 Jul; 13(4):369-79. PubMed ID: 7549896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilevel therapeutic targeting by topoisomerase inhibitors.
    Smith PJ; Souès S
    Br J Cancer Suppl; 1994 Sep; 23():S47-51. PubMed ID: 8075006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
    Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
    Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
    Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
    Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
    Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
    Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
    Yang L; Rowe TC; Liu LF
    Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.